Stress impairs reconsolidation of drug memory via glucocorticoid receptors in the basolateral amygdala.
Relapse to drug taking induced by exposure to cues associated with drugs of abuse is a major challenge to the treatment of drug addiction. Previous studies indicate that drug seeking can be inhibited by disrupting the reconsolidation of a drug-related memory. Stress plays an important role in modulating different stages of memory including reconsolidation, but its role in the reconsolidation of a drug-related memory has not been investigated. Here, we examined the effects of stress and corticosterone on reconsolidation of a drug-related memory using a conditioned place preference (CPP) procedure. We also determined the role of glucocorticoid receptors (GRs) in the basolateral amygdala (BLA) in modulating the effects of stress on reconsolidation of this memory. We found that rats acquired morphine CPP after conditioning, and that this CPP was inhibited by stress given immediately after re-exposure to a previously morphine-paired chamber (a reconsolidation procedure). The disruptive effect of stress on reconsolidation of morphine related memory was prevented by inhibition of corticosterone synthesis with metyrapone or BLA, but not central amygdala (CeA), injections of the glucocorticoid (GR) antagonist RU38486 [(11,17)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one]. Finally, the effect of stress on drug related memory reconsolidation was mimicked by systemic injections of corticosterone or injections of RU28362 [11,17-dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one] (a GR agonist) into BLA, but not the CeA. These results show that stress blocks reconsolidation of a drug-related memory, and this effect is mediated by activation of GRs in the BLA.
Wang
Xiao-Yi
XY
Department of Neuropharmacology, National Institute on Drug Dependence, Peking University, Beijing 100083, China.
Zhao
Mei
M
Ghitza
Udi E
UE
Li
Yan-Qin
YQ
Lu
Lin
L
D000679:Amygdala / Q000187:drug effects / Q000503:physiopathology*; D000701:Analgesics, Opioid / Q000008:administration & dosage; D000732:Androstanols / Q000008:administration & dosage; D000818:Animals; D001245:Association Learning / Q000187:drug effects / Q000502:physiology; D001522:Behavior, Animal; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology; D003345:Corticosterone / Q000494:pharmacology; D004333:Drug Administration Routes; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D008569:Memory Disorders / Q000209:etiology*; D008797:Metyrapone / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology; D009020:Morphine / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000819:agonists / Q000502:physiology*; D012201:Reward; D013315:Stress, Psychological / Q000150:complications*
D000701:Analgesics, Opioid; D000732:Androstanols; D004791:Enzyme Inhibitors; D006727:Hormone Antagonists; D011965:Receptors, Glucocorticoid; D015735:Mifepristone; C049154:11,17-dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one; D009020:Morphine; D003345:Corticosterone; D008797:Metyrapone